Fullife Healthcare ne ₹300 Cr ki funding ki! Supplement business ko milega zabardast boost

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Fullife Healthcare ne ₹300 Cr ki funding ki! Supplement business ko milega zabardast boost
Overview

Fullife Healthcare ne Elev8 aur unke connected investors se ek bada funding round complete kiya hai, jismein unhe **₹300 Crore** mile hain. Ye paisa unke effervescent nutritional supplement business ko aur mazboot banane ke liye use hoga.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Toh bhaiyo aur behno, Fullife Healthcare ke liye ek badi khabar hai! Company ne Elev8 aur unke connected investors se ek dum mast ₹300 Crore ka funding pakka kar liya hai.

Is ₹300 Crore mein se ₹150 Crore toh company ke accounts mein naye equity ke taur par aayenge, aur baaki ke ₹150 Crore existing shareholders ko liquidity dene ke liye secondary purchase mein use honge.

Ye investment Fullife Healthcare ke liye game-changer saabit ho sakta hai, kyunki company India mein effervescent nutritional supplements market mein already sabse badi hai. Is fund se company apna expansion karegi, naye products research karegi aur market mein aur zyada pahunch banayegi.

Aur haan, is poore deal mein legal side ko sambhala Khaitan & Co ne, jinhone agreements ko review karne aur deal ko finalize karne mein madad ki.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.